Compare Globus Medical Inc. Class A Common Stock (GMED) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Teucrium Wheat Fund — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Teucrium Wheat Fund trades at $24.39 (market cap $273.39M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 37.5× Teucrium Wheat Fund's market cap, and Teucrium Wheat Fund is more actively traded (274,868 versus 1,059,528). Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Teucrium Wheat Fund for 42 Days on average.
| GMED | WEAT | |
|---|---|---|
Market Cap | $10.25B | $273.39M |
Volume | 1,059,528 | 274,868 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $96.82 | $28.00 |
52-Week Low | $58.33 | $19.88 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
WEAT trades at $24.28, down 0.74% today, with a bearish technical signal from moving averages. Recent news highlights a 25% year-to-date gain as of July 2026, driven by wheat market dynamics, though inflation concerns persist. Key support is at $24, with resistance at $25. The absence of fundamental ratios like P/E and P/S in the data limits valuation clarity, but the ETF's performance is tied to agricultural commodity trends.
The outlook is cautious due to bearish technical indicators and macroeconomic inflation pressures. Opportunities exist if wheat prices rally, but risks include commodity volatility and Federal Reserve policy impacts. Investors should weigh the ETF's lack of traditional company fundamentals against broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
